Rejoinder to "A hybrid phase I-II/III clinical trial design allowing dose reoptimization in phase III"

Affiliations

¹ Biostatistics Program, School of Public Health, Louisiana State University, New Orleans, Louisiana.
² Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Comment

Andrew G Chapple et al. Biometrics. 2019 Jun.

. 2019 Jun;75(2):389-391.

doi: 10.1111/biom.12991. Epub 2019 Jun 27.

¹ Biostatistics Program, School of Public Health, Louisiana State University, New Orleans, Louisiana.
² Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas.

No abstract available

Comment on

A hybrid phase I-II/III clinical trial design allowing dose re-optimization in phase III.
Chapple AG, Thall PF. Chapple AG, et al. Biometrics. 2019 Jun;75(2):371-381. doi: 10.1111/biom.12994. Epub 2019 Apr 3. Biometrics. 2019. PMID: 30367457 Free PMC article.
Discussion of "A Hybrid Phase I-II/III Clinical Trial Design Allowing Dose Re-Optimization in Phase III" by Andrew G. Chapple and Peter F. Thall.
Leifer ES, Geller NL. Leifer ES, et al. Biometrics. 2019 Jun;75(2):382-384. doi: 10.1111/biom.12993. Epub 2019 Apr 3. Biometrics. 2019. PMID: 30945259 No abstract available.
Discussion of "A hybrid phase I-II/III clinical trial design allowing dose re-optimization in phase III" by Andrew G. Chapple and Peter F. Thall.
Zhou T, Ji Y. Zhou T, et al. Biometrics. 2019 Jun;75(2):385-388. doi: 10.1111/biom.12992. Epub 2019 Apr 3. Biometrics. 2019. PMID: 30945260 No abstract available.